Entasis Therapeutics Holdings Inc
NASDAQ:ETTX
Entasis Therapeutics Holdings Inc
Cash from Financing Activities
Entasis Therapeutics Holdings Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entasis Therapeutics Holdings Inc
NASDAQ:ETTX
|
Cash from Financing Activities
$22.1m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entasis Therapeutics Holdings Inc's Cash from Financing Activities?
Cash from Financing Activities
22.1m
USD
Based on the financial report for Dec 31, 2021, Entasis Therapeutics Holdings Inc's Cash from Financing Activities amounts to 22.1m USD.
What is Entasis Therapeutics Holdings Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-12%
Over the last year, the Cash from Financing Activities growth was -62%. The average annual Cash from Financing Activities growth rates for Entasis Therapeutics Holdings Inc have been -31% over the past three years , -12% over the past five years .